DraftBlue Cross Blue Shield - Rhode IslandPolicy N/A

Whole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders

Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.

Defines medical necessity, prior authorization, and coverage criteria for whole exome sequencing (WES) and whole genome sequencing (WGS), including rapid testing and specific proprietary Genomic Unity® Exome Plus analyses, for Medicare Advantage and Commercial products of BCBSRI.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyWhole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateSep 1, 202643d

Last ReviewMay 20, 2026

Next Review DateMay 20, 2026

Key ActionObtain prior authorization for CPT 0214U/0215U when required and document clinical genetics evaluation and prior testing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2Proprietary test CPT codes named

30-60%Rapid WES/WGS diagnostic yield

25-60%WES diagnostic yield (selected populations)

50+References cited

Related Billing Codes

CPT-0215U-GENOMIC-UNITY-EXOME-PLUS-COMPARATOR-ANALYSIS

CPT 0215U: Genomic Unity® Exome Plus Analysis — Comparator

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

inv-01: Standard WES/WGS — Pediatric unexplained congenital or neurodevelopmental disorders

Covered when ALL of the following are met:

Standard WES/WGS — Pediatric unexplained congenital or neurodevelopmental disorders: 1. Documentation that the individual has been evaluated by a clinician with expertise in clinical genetics, including at minimum a family history and phenotype description, and counseled about the potential risks of genetic testing. 2. There is potential for a change in management and clinical outcome for the individual being tested. 3. A genetic etiology is considered the most likely explanation for the phenotype despite previous genetic testing (eg, chromosomal microarray analysis and/or targeted single-gene testing), OR previous genetic testing has failed to yield a diagnosis and the affected individual is faced with invasive procedures or testing as the next diagnostic step (eg, muscle biopsy).

Trio testing (child + both parents) is preferred when possible but should not delay testing; testing of one available parent is acceptable if both are not immediately available.

inv-02: Rapid WES/WGS — Critically ill neonates/infants

Rapid WES/WGS may be considered medically necessary when BOTH of the following are met:

Rapid WES/WGS — Critically ill neonates/infants: 1. At least one of the following: (a) multiple congenital anomalies; (b) an abnormal laboratory test or clinical features suggesting a genetic disease or complex metabolic phenotype; (c) an abnormal response to standard therapy for a major underlying condition. 2. None of the following reasons for admission to intensive care apply: (a) an infection with normal response to therapy; (b) isolated prematurity; (c) isolated unconjugated hyperbilirubinemia; (d) hypoxic ischemic encephalopathy; (e) a confirmed genetic diagnosis that explains the illness; (f) isolated transient neonatal tachypnea; or (g) a nonviable neonate.

Trio testing preferred when possible but should not delay rapid testing; testing of one available parent may be done if both are not immediately available.

Whole exome sequencing for the diagnosis of genetic disorders in situations that do not meet the specified medical necessity criteria is not covered for Medicare Advantage Plans and is considered not medically necessary for Commercial Products. This exclusion applies to WES performed outside the covered indications (for example, when the required clinical genetics evaluation, potential to change management, or prior testing conditions are not satisfied).

Repeat whole exome sequencing for diagnostic purposes, including re-analysis of prior WES results, is not covered / not medically necessary. The evidence summarized in the policy finds limited direct clinical utility for routine repeat WES or scheduled re-analysis, and while re-analysis can increase diagnostic yield in some studies, the overall evidence is insufficient to establish improved net health outcomes.

Whole exome sequencing used for population or routine screening for genetic disorders is not covered and is considered not medically necessary for both Medicare Advantage and Commercial Products.

This policy is provided for informational purposes and is not a guarantee of payment. Coverage and payment are governed by the member's subscriber agreement or employer agreement, which supersede this policy. For member-specific coverage information, providers should contact the provider call center.

Use of WES for suspected genetic disorders outside the specified covered indications—specifically disorders other than multiple congenital anomalies or neurodevelopmental disorders after standard workup—is considered investigational/insufficient evidence. The policy notes limited and heterogeneous evidence for these other indications and concludes the evidence is insufficient to demonstrate improvement in net health outcomes.

Services determined to be not medically necessary may be denied, and providers may not charge the member for such services unless the member has been informed in advance and has agreed in writing to accept financial responsibility. Providers should follow applicable participation agreements and member-benefit rules.

Covered Indications

inv-24: Evaluation of unexplained congenital or neurodevelopmental disorders in children after standard workup

Standard WES (with trio when possible) may be considered medically necessary when the following are met; reported diagnostic yields 25–60% depending on age, phenotype, and prior workup:

Evaluation of unexplained congenital or neurodevelopmental disorders in children after standard workup: 1. Individual evaluated by a clinician with expertise in clinical genetics with documented family history and phenotype description and pre-test counseling. 2. Testing is expected to have potential to change management or clinical outcome. 3. A genetic etiology is considered most likely despite prior genetic testing (eg, chromosomal microarray and/or targeted single-gene testing), OR prior testing failed to yield a diagnosis and the next diagnostic step would be invasive (eg, muscle biopsy).

Trio testing preferred when possible but should not delay testing; singleton testing acceptable if parents unavailable.

inv-25: Critically ill infants in neonatal or pediatric intensive care with suspected genetic disorder of unknown etiology

Rapid WES/WGS (with trio when possible) may be considered medically necessary in critically ill neonatal/pediatric intensive care patients when the criteria below are met; reported diagnostic yields 30–60% in cited studies and associated changes in management have been described:

Coding

Covered CPT CodesCPTCovered

0214U	Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband
0215U	Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator exome (eg, parent, sibling)

Provider Actions & Authorization

Prior Authorization

Prior authorization required for CPT 0214U and 0215U

Prior authorization is required for Medicare Advantage Plans and is recommended for Commercial Products for Genomic Unity® Exome Plus Analysis — Proband (CPT 0214U) and Comparator (CPT 0215U). Only the ordering physician may be involved in authorization; laboratories are not allowed to obtain authorization on behalf of the ordering physician.

CPT codes: 0214U (Proband) and 0215U (Comparator)
Laboratories must not obtain clinical authorization or participate in the authorization process on behalf of the ordering physician

Prior Authorization

Prior authorization and coverage determined by member agreement

Coverage and prior authorization requirements depend on the member's subscriber/employer agreement; contact the provider call center for member-specific benefits and eligibility information.

Benefits and eligibility are determined by the member's subscriber agreement or employer agreement
For member-specific benefit information, call the provider call center

Definitions

WES — Whole Exome Sequencing

DefinitionWhole exome sequencing (WES) — targeted next-generation sequencing of the subset of the human genome that contains protein-coding DNA (the exome).

Scope of coverageSequences most protein-coding sequence (~85% of heritable disease‑causing variants) covering ~20,000 genes and ~180,000 exons (≈1% of the genome).

Technical limitsDoes not routinely detect intronic/regulatory variants, large chromosomal changes, large deletions/duplications, repeat expansions, or epigenetic changes.

Clinical roleUsed to obtain a molecular diagnosis in patients with suspected genetic disorders not explained by standard clinical workup; trio testing (child + both parents) is preferred when possible to increase diagnostic yield.

WGS — Whole Genome Sequencing

Definition

Eligibility Requirements

No top-level eligibility requirement nodes are specified in this policy.

Not Covered

Whole exome sequencing or whole genome sequencing performed outside the specific covered criteria is not covered (Medicare Advantage) or not medically necessary (Commercial Products). This includes repeat WES (including re-analysis) and WES used for screening purposes. The policy cites limited and heterogeneous evidence for routine use outside defined indications and for re-analysis, and therefore does not support coverage for those scenarios.

This medical policy does not guarantee payment. Coverage exclusions and payment determinations are governed by the member's subscriber or employer agreements. Providers should verify member-specific benefits and eligibility and follow prior authorization and documentation requirements as applicable.

Background

Whole exome sequencing (WES) targets protein-coding regions of the genome (the exome, approximately 1% of the genome) while whole genome sequencing (WGS) includes both coding and noncoding regions. WES/WGS are intended for patients whose disorder remains unexplained after a standard diagnostic workup; trio testing (child plus both parents) is preferred when possible because it increases diagnostic yield and reduces false positives, but testing should not be delayed if trios are not immediately available. Rapid WES/WGS may be appropriate for critically ill neonates or infants in intensive care when specific clinical criteria are met.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyWhole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateSep 1, 202643d

Last ReviewMay 20, 2026

Next Review DateMay 20, 2026

Key ActionObtain prior authorization for CPT 0214U/0215U when required and document clinical genetics evaluation and prior testing.

SourceLink

On This Page

Critically ill infants in neonatal or pediatric intensive care with suspected genetic disorder of unknown etiology: 1. At least one of: (a) multiple congenital anomalies; (b) an abnormal laboratory test or clinical features suggestive of a genetic or complex metabolic disorder; (c) an abnormal response to standard therapy for a major underlying condition. 2. None of the following reasons for ICU admission apply: (a) infection with normal response to therapy; (b) isolated prematurity; (c) isolated unconjugated hyperbilirubinemia; (d) hypoxic ischemic encephalopathy; (e) a confirmed genetic diagnosis that explains the illness; (f) isolated transient neonatal tachypnea; (g) nonviable neonates.

Trio testing preferred when possible but should not delay rapid testing; rapid testing supported by prospective and observational studies reporting yields of ~30–60% and demonstrated impacts on management (eg, avoidance of invasive procedures, medication changes, initiation of palliative care).

inv-26: Diagnosis of suspected genetic disorders across a range of presentations including neurodevelopmental disorders, critically ill infants, unexplained developmental disabilities, retinal disease, epilepsy, and other Mendelian conditions as supported by cited literature.

Diagnosis of suspected genetic disorders across a range of presentations may be supported by the cited literature; clinical contexts with evidence include neurodevelopmental disorders, critically ill infants, unexplained developmental disabilities, retinal disease, epilepsy, and other Mendelian conditions:

Supported clinical presentations and evidence: Multiple published studies and reviews report diagnostic yield and clinical utility of WES/WGS across heterogeneous conditions, including: neurodevelopmental disorders and multiple congenital anomalies (diagnostic yields ~25–60%), critically ill infants in NICU/PICU (rapid sequencing yields ~30–60%), inherited retinal disease, epilepsy, and other Mendelian conditions. The literature includes large case series, prospective cohorts, and randomized or comparative studies documenting diagnostic yield and changes in management.

See references cited for detailed study-level yields and outcomes; trio testing generally increases diagnostic yield.

Step Therapy

Expect standard diagnostic workup (prior targeted testing/CMA) before WES/WGS

Perform a standard diagnostic workup before ordering standard WES/WGS unless rapid testing for a critically ill infant is indicated; this includes prior targeted genetic testing (eg, single-gene tests) or chromosomal microarray when clinically appropriate.

Standard WES/WGS is considered when prior testing (e.g., chromosomal microarray and/or targeted single-gene testing) has been performed and failed to yield a diagnosis, unless rapid testing is indicated for critically ill infants

Note

Ordering physician must handle authorization; labs prohibited from obtaining authorization

Follow ordering and authorization process rules: the ordering physician must be involved in authorization, and laboratories are prohibited from obtaining authorization or participating in the process on behalf of the ordering physician.

Ordering physician shall be involved in authorization, appeal, and related administrative processes
No laboratory representative or third party may obtain authorization on behalf of the ordering physician

Documentation Required

Document clinical genetics evaluation and pre-test counseling

Document that the individual was evaluated by a clinician with expertise in clinical genetics, including at minimum a family history and phenotype description, and that pre-test counseling about risks of genetic testing was provided.

Clinical genetics evaluation with family history and phenotype description required
Pre-test counseling about potential risks must be documented

Documentation Required

Document prior relevant genetic testing and nondiagnostic results

Provide evidence that prior relevant genetic testing (e.g., chromosomal microarray analysis and/or targeted single-gene testing) has been performed and failed to yield a diagnosis when required by the criteria for standard WES/WGS.

Document prior testing such as chromosomal microarray and/or targeted single-gene testing and results showing no diagnosis when applicable

Billing Rule

Verify member benefits and document medical necessity

Verify member-specific benefits and eligibility with the provider call center prior to testing; maintain documentation that supports medical necessity consistent with the member's subscriber or employer agreement.

Confirm benefits/eligibility via the provider call center
Retain documentation supporting medical necessity per subscriber/employer agreement

Denial Risk

Unauthorized lab services will be denied and billed to the laboratory

If a laboratory provides a laboratory service that has not been authorized, that service will be denied and the financial liability will fall to the participating laboratory; such services may not be billed to the member.

Unauthorized laboratory services will be denied as the financial liability of the laboratory
Laboratories may not bill the member for unauthorized services

Denial Risk

Do not allow labs/third parties to support authorization — violation may lead to termination

If a laboratory or third party supports any portion of the authorization process (including obtaining authorization), BCBSRI will deem this a violation of policy and may take severe action up to termination from the BCBSRI provider network.

Support of authorization by a laboratory or third party is a policy violation
Violations may result in termination from the BCBSRI provider network

Denial Risk

Benefit and eligibility determine payment and potential denial

Coverage and payment are determined by the member's subscriber agreement or employer agreement; services determined to be not medically necessary or non-covered under those agreements may be denied or not paid.

Member contract (subscriber/employer agreement) governs coverage and payment
Services deemed not medically necessary may be denied or excluded from payment

Documentation Required

Pre-test counseling by clinical genetics expert required

Pre-test counseling by a clinician with expertise in clinical genetics about potential risks of genetic testing is required and should be documented as part of the clinical evaluation.

Counseling must be performed by a clinician with expertise in clinical genetics
Counseling about potential risks must be documented

Note

Ordering physician must manage authorization and documentation; labs prohibited from obtaining authorization

The ordering physician must be involved in the authorization and documentation process; laboratories are expressly prohibited from obtaining authorization or participating in the authorization process on behalf of the ordering physician.

Ordering physician shall handle authorization and appeals
Laboratories must not obtain authorization on behalf of the ordering physician

Whole genome sequencing (WGS) — next-generation sequencing of the entire genome, including coding and noncoding regions.

Analytic capabilityGreater ability than WES to detect large deletions or duplications in protein‑coding regions and to interrogate noncoding regions.

Data considerationsRequires greater data analytics and interpretation resources compared with WES; technical aspects and platform variability affect coverage and variant calling.

Clinical roleMay be considered when broader genomic interrogation is needed beyond the exome for diagnosis of suspected genetic conditions not explained by standard workup.

Variant interpretation standards (ACMG/AMP)

Reference guidanceStandards and guidelines for interpretation of sequence variants per ACMG/AMP joint consensus recommendation (Richards et al., Genet Med. May 2015).

PurposeProvide a standardized framework for classifying variants (eg, pathogenic, likely pathogenic, uncertain significance, likely benign, benign).

Clinical applicationUsed to guide reporting and clinical decision‑making for variants identified by WES/WGS to support diagnostic conclusions and management.

Catch payer policy changes before they impact reimbursement

Catch payer policy changes before they impact reimbursement

OpenPayer

Whole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders

Related Billing Codes

Coverage Criteria

Covered Indications

Coding

Provider Actions & Authorization

Definitions

Eligibility Requirements

Not Covered

Background